Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-world Evidence in Clinical Decision Making

被引:8
作者
Villines, Todd C. [1 ]
Cziraky, Mark J. [2 ]
Amin, Alpesh N. [3 ]
机构
[1] Univ Virginia Hlth Syst, 1215 Lee St, Charlottesville, VA 22908 USA
[2] HealthCore Inc, Wilmington, DE USA
[3] Univ Calif Irvine, Dept Med, Sch Med, Irvine, CA 92717 USA
来源
CLINICAL MEDICINE INSIGHTS-CARDIOLOGY | 2020年 / 14卷
关键词
Cardiologists; clinical decision making; randomized clinical trials; real-world evidence; survey; DIRECT ORAL ANTICOAGULANTS; ATRIAL-FIBRILLATION; STROKE PREVENTION; TRIALS; RIVAROXABAN; GUIDELINES; WARFARIN; SAFETY;
D O I
10.1177/1179546820953410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Real-world evidence (RWE) provides a potential rich source of additional information to the body of data available from randomized clinical trials (RCTs), but there is a need to understand the strengths and limitations of RWE before it can be applied to clinical practice. To gain insight into current thinking in clinical decision making and utility of different data sources, a representative sampling of US cardiologists selected from the current, active Fellows of the American College of Cardiology (ACC) were surveyed to evaluate their perceptions of findings from RCTs and RWE studies and their application in clinical practice. The survey was conducted online via the ACC web portal between 12 July and 11 August 2017. Of the 548 active ACC Fellows invited as panel members, 173 completed the survey (32% response), most of whom were board certified in general cardiology (n = 119, 69%) or interventional cardiology (n = 40, 23%). The survey results indicated a wide range of familiarity with and utilization of RWE amongst cardiologists. Most cardiologists were familiar with RWE and considered RWE in clinical practice at least some of the time. However, a significant minority of survey respondents had rarely or never applied RWE learnings in their clinical practice, and many did not feel confident in the results of RWE other than registry data. These survey findings suggest that additional education on how to assess and interpret RWE could help physicians to integrate data and learnings from RCTs and RWE to best guide clinical decision making.
引用
收藏
页数:7
相关论文
共 31 条
[1]   Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems [J].
Anderson, Monique L. ;
Califf, Robert M. ;
Sugarman, Jeremy .
CLINICAL TRIALS, 2015, 12 (03) :276-286
[2]   A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality [J].
Austin, Peter C. .
MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) :119-151
[3]   Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice [J].
Beyer-Westendorf, Jan ;
Camm, A. John ;
Coleman, Craig I. ;
Tamayo, C. A. P. T. Sally .
THROMBOSIS AND HAEMOSTASIS, 2016, 116 :S13-S23
[4]   Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation [J].
Camm, A. John ;
Pinto, Fausto J. ;
Hankey, Graeme J. ;
Andreotti, Felicita ;
Hobbs, F. D. Richard .
EUROPACE, 2015, 17 (07) :1007-1017
[6]  
Cziraky M, 2015, APPL CLIN TRIALS, V2017, P1
[7]   Inclusion, Analysis, and Reporting of Sex and Race/Ethnicity in Clinical Trials: Have We Made Progress? [J].
Geller, Stacie E. ;
Koch, Abby ;
Pellettieri, Beth ;
Carnes, Molly .
JOURNAL OF WOMENS HEALTH, 2011, 20 (03) :315-320
[8]   Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation [J].
Graham, David J. ;
Reichman, Marsha E. ;
Wernecke, Michael ;
Hsueh, Hui ;
Izem, Rima ;
Southworth, Mary Ross ;
Wei, Yuqin ;
Liao, Jiemin ;
Goulding, Margie R. ;
Mott, Katrina ;
Chillarige, Yoganand ;
MaCurdy, Thomas E. ;
Worrall, Chris ;
Kelman, Jeffrey A. .
JAMA INTERNAL MEDICINE, 2016, 176 (11) :1662-1671
[9]   Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? [J].
Hanley, Colleen M. ;
Kowey, Peter R. .
JOURNAL OF THORACIC DISEASE, 2015, 7 (02) :165-171
[10]  
Hernandez A., 2017, FRAMEWORK REGULATORY